EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinitionSeptember 20, 2021DiabetesCardiologyEndocrinology
A new weight loss threshold for T2d remission after bariatric surgery?September 20, 2021DiabetesObesityEndocrinologyCardiology
Premature menopause a ‘warning sign’ for greater ASCVD riskSeptember 17, 2021DiabetesWomen's HealthCardiology
COVID vaccine preprint study prompts Twitter outrageSeptember 16, 2021COVID-19 UpdatesCardiologyVaccines
Texts boost activity, quality of life in patients with heart failure and diabetesSeptember 16, 2021DiabetesCardiology
Weight-loss surgery linked to fewer cardiovascular events, more so with RYGBSeptember 15, 2021ObesityDiabetesCardiologyGastroenterology
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEFSeptember 14, 2021DiabetesObesityCardiologyEndocrinology
Study gives bleeding risk estimates for VTE patients on anticoagulantsSeptember 13, 2021CardiologyHematology
Two swings, two misses with colchicine, Vascepa in COVID-19September 1, 2021COVID-19 UpdatesPulmonologyCardiology
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEFAugust 31, 2021DiabetesCardiologyEndocrinology
